Home › NCT07203287

Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease

Who can join

Ages 18 to 80 · All sexes · Healthy volunteers welcome

Inclusion Criteria:

* The subject is able and willing to provide and sign informed consent
* The subject must be between 18 and 80 years of age
* The subject should have chronic kidney disease as defined by glomerular filtration rate
* The surgery must require general anesthesia with endotracheal intubation and neuromuscular blockade

Exclusion Criteria:

* Any patient under the age of 18
* Any patient over the age of 80
* Any patient with end stage renal disease
* Any patient requiring dialysis
* Patients presenting for Renal Transplantation
* Pregnant Female
* Any patient in the correctional system
* Urgent or Emergent procedure
* The surgery requires intubation post-operatively
* Documented allergy to Rocuronium, Sugammadex, Cisatracurium or Neostigmine

About the study

The purpose of the study is to determine which combination of neuromuscular blocking agent and reversal agent is safer to use during anesthesia for patients with chronic kidney disease. The main question it aims to answer is

"The use of Cisatracurium with neostigmine leads to less post-operative pulmonary complications than Rocuronium with sugammadex."

What is being tested

• Rocuronium (drug)
• Cisatracurium (drug)
• Sugammadex (drug)
• Neostigmine (drug)

Sponsor: The University of Texas Medical Branch, Galveston · Participants: 490 · Started: Aug 26, 2025

Contact the study team

• Michael Kinsky, MD · Phone: 409-772-1011

Official record on ClinicalTrials.gov — NCT07203287

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.